| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | 0.026 | 0.9 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | Sorafenib | FIMM | pan-cancer | AAC | -0.024 | 0.9 |
| mRNA | isoevodiamine | CTRPv2 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.0053 | 0.9 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | 0.0072 | 0.9 |
| mRNA | CHEMBL374350 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | 0.0048 | 0.9 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |